MIM
CTKB icon

MetLife Investment Management’s Cytek Biosciences CTKB Stock Holding History

MetLife Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
68,692
+4,175
+6% +$17.8K ﹤0.01% 2201
2026
Q1 		$282K Buy
64,517
+6,759
+12% +$31.9K ﹤0.01% 2040
2025
Q4 		$292K Sell
57,758
-12,122
-17% -$56.3K ﹤0.01% 2087
2025
Q3 		$242K Sell
69,880
-3,418
-5% -$12.8K ﹤0.01% 2208
2025
Q2 		$249K Buy
73,298
+5,567
+8% +$18.6K ﹤0.01% 2071
2025
Q1 		$272K Sell
67,731
-6,667
-9% -$34.6K ﹤0.01% 2030
2024
Q4 		$483K Buy
74,398
+4,158
+6% +$24.8K ﹤0.01% 1822
2024
Q3 		$389K Hold
70,240
– – ﹤0.01% 1918
2024
Q2 		$392K Buy
70,240
+7,258
+12% +$43.6K ﹤0.01% 1857
2024
Q1 		$423K Hold
62,982
– – ﹤0.01% 1770
2023
Q4 		$574K Hold
62,982
– – ﹤0.01% 1608
2023
Q3 		$348K Hold
62,982
– – ﹤0.01% 1849
2023
Q2 		$538K Buy
62,982
+1,951
+3% +$17.5K ﹤0.01% 1652
2023
Q1 		$561K Hold
61,031
– – ﹤0.01% 1576
2022
Q4 		$623K Hold
61,031
– – ﹤0.01% 1497
2022
Q3 		$898K Hold
61,031
– – 0.01% 1245
2022
Q2 		$655K Buy
61,031
+6,277
+11% +$62.5K 0.01% 1481
2022
Q1 		$590K Buy
54,754
+48,305
+749% +$652K ﹤0.01% 1668
2021
Q4 		$105K Hold
6,449
– – ﹤0.01% 2388
2021
Q3 		$138K Buy
+6,449
New +$152K ﹤0.01% 2288

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's CTKB Position: Q2 2026 in Review

MetLife Investment Management increased its Cytek Biosciences (CTKB) stake by 6.5% in Q2 2026, buying an estimated $17.8K and bringing the position to 68,692 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

MetLife Investment Management first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $898K in Q3 2022. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • MetLife Investment Management held 68,692 shares of Cytek Biosciences worth $304K as of Q2 2026.
  • MetLife Investment Management bought 4,175 Cytek Biosciences shares in Q2 2026, an estimated $17.8K.
  • Cytek Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2201 holding.
  • MetLife Investment Management first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • MetLife Investment Management's Cytek Biosciences position peaked at $898K in Q3 2022.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.